Early Parkinson Disease - Dopaminergic Therapy for Motor Symptoms

AAN GUIDELINES Product Bundle brought to you by Guideline Central.

Issue link: https://eguideline.guidelinecentral.com/i/1512412

Contents of this Issue


Page 4 of 4

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2021 All rights reserved AANPAR10213a Disclaimer is pocket guide attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is pocket guide should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Abbreviations AAN, American Academy of Neurolog y; CR, controlled-release; DA, dopamine agonist; DAWS, dopamine agonist withdrawal syndrome; ICD, impulse control disorder; MAO-B, monoamine oxidase type B; PD, Parkinson disease; QUIP, Questionnaire for Impulsive- Compulsive Disorders in Parkinson Disease Source Pringsheim T et al. Practice guideline summary: Dopaminergic therapy for motor symptoms in early Parkinson disease. Neurolog y. 2021 November 15. doi: 10.1212/ WNL.0000000000012868 Classification of Management Recommendations Classification Definition Level (A) Denotes a practice recommendation that must be done. In almost all circumstances, adherence to the recommendation will improve health- related outcomes. Almost all patients in this circumstance would desire that the recommendation be followed. Level (B) Corresponds to the helping verb should. Should recommendations tend to be more common, as the requirements are less stringent but still based on the evidence and benefit-risk profile. Level (C) Corresponds to the helping verb may. May recommendations represent the lowest allowable recommendation level the AAN considers useful within the scope of clinical practice and can accommodate the highest degree of practice variation. Level (U) Indicates that the available evidence is insufficient to support or refute the efficacy of an intervention. Level (R) Assigned when the balance of benefits and harms is unknown and the intervention is known to be exorbitantly expensive or have important risks. is level designates that the intervention should not be used outside of a research setting.

Articles in this issue

Links on this page

view archives of AAN GUIDELINES Bundle - Early Parkinson Disease - Dopaminergic Therapy for Motor Symptoms